SELLAS Life Sciences’ lead therapy candidate galinpepimut-S (GPS) received orphan medicinal product designation from the European Medicines Agency for the treatment of multiple myeloma…
Leukogene Therapeutics, a startup company from the Medical University of South Carolina (MUSC), has been awarded a $2 million Small Business Technology…
Backed by former Major League Baseball All-Stars Dave Winfield and Steve Garvey, Amgen has launched a program aimed at raising awareness of multiple myeloma,…
The European Commission has approved the anti-CD38 antibody Darzalex (daratumumab), in combination with standard therapy, for newly diagnosed multiple myeloma patients who cannot receive a stem…
Poseida Therapeutics’ CAR T-cell therapy candidate P-BCMA-101 is showing superior safety over alternatives and significant effectiveness in patients with relapsed or refractory…
Smoldering multiple myeloma (SMM) — an early, asymptomatic precursor of multiple myeloma — often exhibits similar genetic alterations as the full-blown disease, suggesting that patients could…
The combination of two blood tests routinely ordered by general practitioners could speed the diagnosis of myeloma, according to a new study. The research,…
Maintenance treatments containing the immunomodulatory therapy Revlimid (lenalidomide) are the best option for patients with multiple myeloma, according to a recent meta-analysis. The study, “…
Amgen is seeking to expand the approval of its proteasome inhibitor Kyprolis (carfilzomib) in the U.S. to include once-weekly dosing combined with dexamethasone for…
The U.S. Food and Drug Administration granted priority review to Bristol-Myers Squibb’s supplemental Biologics License Application (sBLA) for Empliciti (elotuzumab) combined with Pomalyst (pomalidomide) and…
